A Phase 4 interventional study of Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1 and Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2 in Hemophilia A, sponsored by Bayer. Completed at 10 sites in China. Open to male participants aged 0 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.
Among the 57 studies in Hemophilia A by Bayer, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 4, and was the 50th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Brazil, Canada and 8 more countries
Ages 7–12
Bayer · Sites in Korea, Republic of
Ages 12+
Bayer
Ages 18+
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 0 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 9 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2020.
This study's enrollment of 45 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 31 interventional studies, 67 across the 26 observational. Of the 50 that completed or were terminated, 14 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
3 of the studies in Hemophilia A by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03932201BayerEvaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A | 2026-12-31 |
| NCT05643560BayerAn Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A. | 2027-03-31 |
| NCT04461639BayerStudy to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Hemophilia A by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A (PTPs):
Part B (PUPs/MTPs):
Exclusion Criteria:
Part A (PTPs):
Part B (PUPs/MTPs):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Previously treated severe hemophilia A patients (PTPs) \<12 years of age
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1
Previously treated severe hemophilia A patients (PTPs) ≥12 to 65 years of age
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2
Previously untreated/minimally treated severe hemophilia A patients (PUPs/MTPs) \<6 years of age
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3
25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months. The dose decisions are at the discretion of the investigator.
12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months. \>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months. The dose decisions are at the discretion of the investigator.
15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week. The dose decisions are at the discretion of the investigator.
Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part A
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
Time frame: Up to 6 months
Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part B
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
Time frame: Up to 48 hours post-infusion during 6 months
Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part A
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
Time frame: Up to 48 hours post-infusion during 6 months
Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part B
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
Time frame: Up to 51 exposure days
Number of Infusions Per Bleeding Episode
The mean value of number of infusions for the treatment of one bleed to achieve hemostasis is reported.
Time frame: Part A: up to 6 months; Part B: up to 51 exposure days
Number of Surgeries Per Physician's Assessment of Adequacy of Hemostasis in Minor Surgery
For participants who underwent minor surgeries during the study, investigators were ask to assess the adequacy of hemostasis during the surgeries as excellent, good, moderate or poor. Number of surgeries per assessment is reported.
Time frame: Part A: up to 6 months; Part B: up to 51 exposure days
FVIII In-vivo Recovery in Part B
Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.
Time frame: At baseline, Visit 6 (ED 20), unscheduled visit and final visit, up to 51 exposure days
Factor VIII Inhibitor Development by the Nijmegen Bethesda Assay
Number of participants who developed a positive Factor VIII (FVIII) inhibitor level (≥0.6 Bethesda unit \[BU/mL\]) during the study is reported.
Time frame: Part A: up to 6 months; Part B: up to 51 exposure days
Number of Participants With Treatment-emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence in a participant, associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect; another medical important serious event as judged by the investigator. AEs or SAEs were considered to be treatment emergent (TEAEs or TESAEs) if they started after the first KOVALTRY infusion and up to 3 days after the last dose.
Time frame: Part A: up to 6 months; Part B: up to 51 exposure days
FVIII In-vivo Recovery in Part A
Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.
Time frame: At baseline, Month 2 and final visit, up to 6 months
Maximum Observed Concentration of FVIII in Plasma (Cmax) in Part A
For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.
Time frame: at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years
Area Under the Plasma Concentration of FVIII Versus Time Curve From Zero to Infinity (AUC) in Part A
For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.
Time frame: at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years
Half-life (t1/2) of FVIII in Plasma in Part A
For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.
Time frame: at baseline for PTPs < 12 Years and at baseline and final visit (month 6) for PTPs >= 12 Years
Number of Participants Without Bleeding Episode
Number of participants who did not experience any bleed during the prophylaxis treatment period or within 48 hours of previous prophylaxis infusion is reported.
Time frame: During prophylaxis treatment in Part A: up to 6 months; Part B: up to 51 exposure days
Number of Bleeds Per Assessment of Response to Treatment of Bleeds
Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Number of bleeds per assessment is reported.
Time frame: Part A: up to 6 months; Part B: up to 51 exposure days
The Part A of study was conducted in multicenter in China between 22 SEP 2020 and 04 JAN 2022. The Part B of study was conducted in multicenter in China between 07 SEP 2021 and 15 MAR 2024.
| Milestone | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Started | 30 | 12 | 2 | 1 |
| Completed | 30 | 12 | 1 | 1 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Patient/guardian decision | 0 | 0 | 1 | 0 |
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
| Bleed per year | Part A: PTPs ≥12 Years | Part A: PTPs <12 Years |
|---|---|---|
| Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part A | 1.86 ± 2.54 | 3.38 ± 4.17 |
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
| Bleed per year | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|
| Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part B | 0.00 ± 0.00 | 0.00 ± 0.00 |
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred within 48 hours of previous prophylaxis infusion is reported for previously treated patients (PTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
| Bleed per year | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years |
|---|---|---|
| Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part A | 2.26 ± 3.10 | 1.36 ± 2.19 |
Annualized number (mean +/- standard deviation) of all bleeding episodes that occurred during the prophylaxis treatment period is reported for previously untreated/minimally treated patients (PUPs/MTPs). All bleeding episodes: sum of spontaneous bleeds and trauma bleeds exclude bleeding due to surgery.
| Bleed per year | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|
| Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part B | 1.13 ± 1.60 | 2.05 ± 0 |
The mean value of number of infusions for the treatment of one bleed to achieve hemostasis is reported.
| Infusion | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Number of Infusions Per Bleeding Episode | 1.78 ± 2.28 | 1.45 ± 1.29 | 14.00 ± 0.00 | 1.00 ± 0.00 |
For participants who underwent minor surgeries during the study, investigators were ask to assess the adequacy of hemostasis during the surgeries as excellent, good, moderate or poor. Number of surgeries per assessment is reported.
| surgery | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Total minor surgeries | 2 | 2 | — | — |
| Surgeries with EXCELLENT adequacy of hemostasis | 2 | 2 | — | — |
Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.
| IU/dL per IU/kg | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|
| Baseline (Unscheduled visit for PUP) | 1.90 ± 0.00 | 1.86 ± 0.00 |
| Visit 6 (ED 20) | 0.91 ± 0.00 | 1.22 ± 0.00 |
| Final visit | 1.55 ± 0.00 | — |
Number of participants who developed a positive Factor VIII (FVIII) inhibitor level (≥0.6 Bethesda unit \[BU/mL\]) during the study is reported.
| Participants | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Factor VIII Inhibitor Development by the Nijmegen Bethesda Assay | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant, associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect; another medical important serious event as judged by the investigator. AEs or SAEs were considered to be treatment emergent (TEAEs or TESAEs) if they started after the first KOVALTRY infusion and up to 3 days after the last dose.
| Participants | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Any TEAE | 13 | 3 | 1 | 1 |
| Maximum intensity for any TEAE - Mild | 10 | 3 | 1 | 1 |
| Maximum intensity for any TEAE - Moderate | 2 | 0 | 0 | 0 |
| Maximum intensity for any TEAE - Severe | 1 | 0 | 0 | 0 |
| Any study drug-related TEAE | 1 | 0 | 0 | 0 |
| Any TESAE | 2 | 0 | 0 | 0 |
| TEAE with outcome death | 0 | 0 | 0 | 0 |
Number of participants who did not experience any bleed during the prophylaxis treatment period or within 48 hours of previous prophylaxis infusion is reported.
| Participants | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| During prophylaxis treatment | 13 | 7 | 1 | 0 |
| Within 48 hours | 16 | 8 | 2 | 1 |
Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Number of bleeds per assessment is reported.
| Bleeds | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Total bleeds | 51 | 11 | 1 | 1 |
| Bleeds without response assessment to treatment | 7 | 1 | 0 | 0 |
| Bleeds with EXCELLENT response to treatment | 4 | 5 | 0 | 0 |
| Bleeds with GOOD response to treatment | 25 | 2 | 0 | 1 |
| Bleeds with MODERATE response to treatment | 14 | 3 | 1 | 0 |
| Bleeds with POOR response to treatment | 1 | 0 | 0 | 0 |
Incremental recovery of Factor VIII (FVIII) was determined by collecting blood samples pre-infusion and 15-30 minutes after the end of the infusion. Mean recovery values at different time points are reported.
| IU/dL per IU/kg | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years |
|---|---|---|
| Baseline | 1.82 ± 0.26 | 2.03 ± 0.46 |
| Month 2 | 1.86 ± 0.32 | 2.12 ± 0.42 |
| Final visit | 1.85 ± 0.33 | 2.06 ± 0.37 |
For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.
| IU/dL | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years |
|---|---|---|
| Baseline | 95.20 ± 15.24 | 114.64 ± 15.77 |
| Final Visit/ Early Termination | — | 115.95 ± 17.47 |
For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.
| h*IU/dL | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years |
|---|---|---|
| Baseline | 1292.97 ± 22.87 | 1519.38 ± 32.38 |
| Final Visit/ Early Termination | — | 1559.29 ± 26.16 |
For the assessment, participants were administered a dose of 50 IU/kg KOVALTRY. Participants must have no signs or symptoms of an acute bleeding episode. For participants below 12 years, the evaluation was only performed once at baseline. For adolescents/adult participants 12 years or older, the evaluation was performed twice at baseline and at final visit.
| Hour | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years |
|---|---|---|
| Baseline | 10.3655 ± 21.22 | 11.8605 ± 19.25 |
| Final Visit/ Early Termination | — | 11.2630 ± 17.29 |
Collected over From the first infusion to three days after last infusion, an average of 6 months for Part A and 4 months for Part B. Adverse event reporting for deaths (all causes) considers all deaths that occurred at any time during the study before the last contact. Adverse event reporting for deaths (all causes) considers all deaths that occurred at any time during the study before the last contact.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: PTPs >=12 Years | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Part A: PTPs <12 Years | 0/30 (0%) | 2/30 (6.7%) | 8/30 (26.7%) |
| Part B: PUPs <6 Years | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part B: MTPs <6 Years | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Part A: PTPs >=12 Years | Part A: PTPs <12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/12 | 1/30 | 0/2 | 0/1 |
| EpilepsyNervous system disorders | 0/12 | 1/30 | 0/2 | 0/1 |
| Event | Part A: PTPs >=12 Years | Part A: PTPs <12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years |
|---|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 0/12 | 0/30 | 0/2 | 1/1 |
| COVID-19Infections and infestations | 0/12 | 0/30 | 0/2 | 1/1 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/30 | 1/2 | 0/1 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/12 | 0/30 | 1/2 | 0/1 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/12 | 0/30 | 1/2 | 0/1 |
| Upper respiratory tract infectionInfections and infestations | 1/12 | 5/30 | 0/2 | 0/1 |
| TonsillitisInfections and infestations | 0/12 | 4/30 | 0/2 | 0/1 |
| Duodenal ulcerGastrointestinal disorders | 1/12 | 0/30 | 0/2 | 0/1 |
| HypertensionVascular disorders | 1/12 | 0/30 | 0/2 | 0/1 |
| Age, Customized(Participants) | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years | Total |
|---|---|---|---|---|---|
| Infants and toddlers (28 days-23 months) | 0 | 0 | 1 | 0 | 1 |
| Children (2-11 years) | 30 | 0 | 1 | 1 | 32 |
| Adolescents (12-17 years) | 0 | 5 | 0 | 0 | 5 |
| Adults (18-64 years) | 0 | 7 | 0 | 0 | 7 |
| Sex: Female, Male(Participants) | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 30 | 12 | 2 | 1 | 45 |
| Race (NIH/OMB)(Participants) | Part A: PTPs <12 Years | Part A: PTPs ≥12 Years | Part B: PUPs <6 Years | Part B: MTPs <6 Years | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 30 | 12 | 2 | 1 | 45 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Sep 2020 to primary completion in Mar 2024, 41 months.
Results were first posted in Apr 2025, 1 year 1 month after primary completion.
Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 41 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.